Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TOWA PHARMACEUTICAL CO., LTD.

(4553)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Towa Pharmaceutical Co., Ltd. : The underlying trend is in force again

09/01/2021 | 10:07am EDT
long trade
Target price hit
Entry price : 2952¥ | Target : 3080¥ | Stop-loss : 2810¥ | Potential : 4.34%
Towa Pharmaceutical Co., Ltd.'s shares display attractive technical aspects to anticipate a comeback of the underlying trend.
Investors have an opportunity to buy the stock and target the ¥ 3080.
Towa Pharmaceutical Co., Ltd. : Towa Pharmaceutical Co., Ltd. : The underlying trend is in force again
Summary
  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths
  • Its low valuation, with P/E ratio at 9.64 and 9.38 for the ongoing fiscal year and 2023 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • The company appears to be poorly valued given its net asset value.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

© MarketScreener.com 2021
Stocks mentioned in the article
ChangeLast1st jan.
TOWA CORPORATION -2.29% 2428 End-of-day quote.15.56%
TOWA PHARMACEUTICAL CO., LTD. 1.17% 3450 End-of-day quote.80.25%

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials
Sales 2022 171 B 1 504 M 1 504 M
Net income 2022 15 731 M 138 M 138 M
Net Debt 2022 67 366 M 591 M 591 M
P/E ratio 2022 10,8x
Yield 2022 1,50%
Capitalization 170 B 1 486 M 1 490 M
EV / Sales 2022 1,38x
EV / Sales 2023 1,32x
Nbr of Employees 3 456
Free-Float 47,7%
Upcoming event on TOWA PHARMACEUTICAL CO., LTD.
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 3 450,00 JPY
Average target price 3 364,29 JPY
Spread / Average Target -2,48%
EPS Revisions
Managers and Directors
Itsuro Yoshida President & Representative Director
Kenichi Inoue Senior Executive Officer & GM-Administration
Norikazu Eiki Independent Director
Kaori Oishi Independent Outside Director
Kenryo Goto Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
TOWA PHARMACEUTICAL CO., LTD.80.25%1 486
JOHNSON & JOHNSON4.07%431 148
ROCHE HOLDING AG13.98%333 101
PFIZER, INC.14.34%239 966
NOVO NORDISK A/S56.26%238 738
ELI LILLY AND COMPANY44.35%220 952